Search results
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Ram Page· 4 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
Bronchiolitis: Two French studies demonstrate the effectiveness of nirsevimab to protect infants
Medical Xpress· 7 days agoAfter a 2022–2023 season marked by a severe epidemic of bronchiolitis due to respiratory syncytial...
Sustained bias of spatial attention in a 3 T MRI scanner - Scientific Reports
Nature· 2 days agoWhen lying inside a MRI scanner and even in the absence of any motion, the static magnetic field of MRI scanners induces a magneto-hydrodynamic stimulation of subjects’ vestibular organ (MVS ...
Determinants of incomplete penta vaccination among children aged 12 to 23 months in South-West...
Nature· 5 days agoA Community based case–control study was conducted at Illu Aba Bor, mettu district, south west Ethiopia from April 24-May 23, 2022. Mettu is located in Oromia Regional State at a distance of ...
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma - Blood...
Nature· 5 days agoB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 1 day agoLate-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with ...
Current COVID boosters offer good protection against severe outcomes but less so against JN.1
Center for Infectious Disease Research and Policy· 5 days agoThe current COVID-19 boosters targeting the Omicron XBB.1.5 subvariant are still offering solid...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoTruqap™ (capivasertib) plus fulvestrant now available in Canada Canada NewsWire MISSISSAUGA, ON, May 31, 2024 MISSISSAUGA, ON, May 31, 2024 /CNW/ - AstraZeneca is pleased to announce that Truqap™ (capivasertib) in combination with fulvestrant is
Nanoform's biologics technology showcased by large pharma at drug delivery conference;...
FOX 23 News Albany· 6 days agoManufacturing of GMP material in Project Nanoenzalutamide commenced. Fimea's two-day inspection of...
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial...
WLNS Lansing· 3 days agoJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase 2b HERIZON-BTC-01 clinical trial ...
